TLDR: Salesforce is significantly expanding its AI-driven ‘agentic offerings’ within its Life Sciences Cloud, particularly with the Customer Engagement component set for September 2025. This move is a strategic response to the impending separation from Veeva Systems, aiming to provide advanced autonomous agents for tasks ranging from clinical trials to customer engagement, with early adoption from companies like Takeda and a key partnership with IQVIA.
Salesforce is making a significant push into the life sciences sector by scaling its artificial intelligence (AI) capabilities, introducing advanced ‘agentic offerings’ within its Life Sciences Cloud. This strategic expansion, highlighted by the upcoming General Availability of the Customer Engagement component in September 2025, comes as Salesforce prepares for a major platform shift following the non-renewal of its long-standing partnership with Veeva Systems.
Veeva CRM, which has dominated approximately 80% of the life sciences CRM market and operated on Salesforce’s platform since 2007, will see its platform agreement with Salesforce conclude after September 2025. While Veeva CRM on Salesforce will remain supported until September 2030, new customers have been directed to Veeva’s Vault CRM since April 2024. This separation necessitates a comprehensive re-evaluation of technology stacks, integrations, and data strategies for thousands of life sciences organizations.
In response, Salesforce is bolstering its Life Sciences Cloud, which already features live clinical-trial and patient-services functionalities. The forthcoming Customer Engagement component will introduce a field-ready mobile experience, seamlessly integrating Data Cloud insights and Salesforce’s ‘Agentforce’ into the workflows of sales representatives. Agentforce, powered by the sophisticated Atlas Reasoning Engine, is designed to empower AI agents to autonomously handle complex tasks. This includes automated capture of visit notes, generation of summaries, real-time compliance checks, and providing ‘next-best-action’ recommendations. Sales representatives will be able to leverage Agentforce for specific queries, such as optimizing visit plan attainment, receiving tailored recommendations, and automating visit planning, thereby transforming even routine tasks.
Key industry players are already aligning with Salesforce’s vision. Pharmaceutical giant Takeda has signed on as an early adopter of the new offerings. Furthermore, IQVIA, a prominent data provider in the life sciences sector, has licensed its technology to Salesforce, embedding its CRM capabilities, analytics, and data directly into Salesforce’s Life Sciences Cloud. This collaboration is expected to enhance the platform’s data-driven insights and operational efficiency.
Leading this strategic initiative for Salesforce’s clinical, medical, and commercial data play is Frank Defesche, SVP & GM of Life Sciences. Defesche, who previously spent 16 years contributing to Veeva’s market leadership before returning to Salesforce, views the end of the Salesforce–Veeva partnership as an opportunity for direct competition, which he believes will ultimately benefit the market.
Also Read:
- Salesforce’s Finance Chief Leverages AI for Enhanced Operations and Strategic Growth
- Salesforce Bolsters Data Cloud with Acquisition of AI-Powered Waii for Conversational Data Access
The move underscores Salesforce’s significant ‘AI bet’ in the life sciences sector, aiming to provide solutions that move beyond traditional AI assistants to function as skilled, autonomous team members. This aligns with broader industry trends where businesses, including those in ASEAN, are increasingly embracing AI to drive transformation, with 80% of global IT leaders agreeing that AI agents will create new security opportunities.
